Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
CELG's Cash to Debt is ranked lower than
86% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CELG: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.90 Max: No Debt
Current: 0.46
Equity to Asset 0.22
CELG's Equity to Asset is ranked lower than
87% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CELG: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s Equity to Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.60 Max: 0.92
Current: 0.22
-0.68
0.92
Interest Coverage 7.26
CELG's Interest Coverage is ranked lower than
90% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 7.26 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 8.8  Med: 27.63 Max: 428.04
Current: 7.26
8.8
428.04
F-Score: 5
Z-Score: 3.49
M-Score: -2.34
WACC vs ROIC
14.83%
20.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.36
CELG's Operating margin (%) is ranked higher than
88% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CELG: 24.36 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s Operating margin (%) Range Over the Past 10 Years
Min: -64.94  Med: 28.83 Max: 32.84
Current: 24.36
-64.94
32.84
Net-margin (%) 17.31
CELG's Net-margin (%) is ranked higher than
85% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CELG: 17.31 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s Net-margin (%) Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 17.31
-68.02
28.88
ROE (%) 25.92
CELG's ROE (%) is ranked higher than
94% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CELG: 25.92 )
Ranked among companies with meaningful ROE (%) only.
CELG' s ROE (%) Range Over the Past 10 Years
Min: -48.42  Med: 18.34 Max: 33.02
Current: 25.92
-48.42
33.02
ROA (%) 7.49
CELG's ROA (%) is ranked higher than
88% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CELG: 7.49 )
Ranked among companies with meaningful ROA (%) only.
CELG' s ROA (%) Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.49
-38.07
15.8
ROC (Joel Greenblatt) (%) 203.35
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CELG: 203.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -421.4  Med: 147.49 Max: 212.3
Current: 203.35
-421.4
212.3
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
79% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CELG: 20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 36.75 Max: 166.8
Current: 20.6
0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CELG: 20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 23.40 Max: 75.6
Current: 20.4
0
75.6
EPS Growth (3Y)(%) 18.90
CELG's EPS Growth (3Y)(%) is ranked higher than
77% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CELG: 18.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: 25.70 Max: 113.8
Current: 18.9
-60.8
113.8
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CELG Guru Trades in Q1 2015

Murray Stahl 5,000 sh (New)
Mairs and Power 1,776 sh (New)
Ray Dalio 24,296 sh (New)
Jim Simons 425,600 sh (New)
Lee Ainslie 2,230 sh (New)
Joel Greenblatt 17,987 sh (+75.33%)
RS Investment Management 97,369 sh (+27.31%)
Pioneer Investments 3,475,247 sh (+2.92%)
Ken Fisher 229,918 sh (+1.14%)
Steven Cohen 1,000,200 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 24,940 sh (-0.08%)
Ronald Muhlenkamp 85,540 sh (-0.81%)
Paul Tudor Jones 3,180 sh (-15.78%)
Stanley Druckenmiller 195,975 sh (-54.85%)
» More
Q2 2015

CELG Guru Trades in Q2 2015

Ken Heebner 110,000 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 21,062 sh (+562.33%)
Jim Simons 1,006,838 sh (+136.57%)
RS Investment Management 106,224 sh (+9.09%)
Pioneer Investments 3,523,050 sh (+1.38%)
Lee Ainslie 2,230 sh (unchged)
Murray Stahl 5,000 sh (unchged)
Mairs and Power 1,776 sh (unchged)
Ronald Muhlenkamp Sold Out
Stanley Druckenmiller Sold Out
Ray Dalio Sold Out
Ken Fisher 224,399 sh (-2.40%)
Mario Gabelli 24,265 sh (-2.71%)
Joel Greenblatt 7,778 sh (-56.76%)
» More
Q3 2015

CELG Guru Trades in Q3 2015

John Burbank 174,768 sh (New)
Murray Stahl 8,000 sh (+60.00%)
Louis Moore Bacon 80,000 sh (+60.00%)
RS Investment Management 130,238 sh (+22.61%)
Mario Gabelli 29,325 sh (+20.85%)
Mairs and Power 2,086 sh (+17.45%)
Ken Fisher 244,564 sh (+8.99%)
Pioneer Investments 3,637,052 sh (+3.24%)
Ken Heebner Sold Out
Lee Ainslie 2,090 sh (-6.28%)
Joel Greenblatt 6,344 sh (-18.44%)
Paul Tudor Jones 8,020 sh (-61.92%)
Jim Simons 378,633 sh (-62.39%)
» More
Q4 2015

CELG Guru Trades in Q4 2015

Pioneer Investments 3,675,883 sh (+1.07%)
Ken Fisher 245,460 sh (+0.37%)
Jim Simons Sold Out
Mario Gabelli 29,270 sh (-0.19%)
RS Investment Management 129,300 sh (-0.72%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 51.71
CELG's P/E(ttm) is ranked lower than
73% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 26.73 vs. CELG: 51.71 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.92  Med: 48.92 Max: 536.22
Current: 51.71
17.92
536.22
Forward P/E 13.89
CELG's Forward P/E is ranked higher than
60% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. CELG: 13.89 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 51.44
CELG's PE(NRI) is ranked lower than
67% of the 271 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. CELG: 51.44 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s PE(NRI) Range Over the Past 10 Years
Min: 17.92  Med: 48.73 Max: 482.6
Current: 51.44
17.92
482.6
P/B 13.58
CELG's P/B is ranked lower than
99.99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CELG: 13.58 )
Ranked among companies with meaningful P/B only.
CELG' s P/B Range Over the Past 10 Years
Min: 4.02  Med: 9.32 Max: 23.65
Current: 13.58
4.02
23.65
P/S 9.67
CELG's P/S is ranked lower than
52% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. CELG: 9.67 )
Ranked among companies with meaningful P/S only.
CELG' s P/S Range Over the Past 10 Years
Min: 5.41  Med: 10.64 Max: 27.64
Current: 9.67
5.41
27.64
PFCF 41.50
CELG's PFCF is ranked lower than
66% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 30.10 vs. CELG: 41.50 )
Ranked among companies with meaningful PFCF only.
CELG' s PFCF Range Over the Past 10 Years
Min: 15.03  Med: 36.67 Max: 2926
Current: 41.5
15.03
2926
POCF 37.56
CELG's POCF is ranked lower than
66% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. CELG: 37.56 )
Ranked among companies with meaningful POCF only.
CELG' s POCF Range Over the Past 10 Years
Min: 13.95  Med: 34.60 Max: 1407
Current: 37.56
13.95
1407
EV-to-EBIT 40.60
CELG's EV-to-EBIT is ranked lower than
73% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. CELG: 40.60 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 36.00 Max: 156.6
Current: 40.6
-28.6
156.6
EV-to-EBITDA 34.72
CELG's EV-to-EBITDA is ranked lower than
75% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. CELG: 34.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 29.60 Max: 132.5
Current: 34.72
-31.4
132.5
PEG 2.24
CELG's PEG is ranked higher than
56% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. CELG: 2.24 )
Ranked among companies with meaningful PEG only.
CELG' s PEG Range Over the Past 10 Years
Min: 1.38  Med: 1.96 Max: 3.05
Current: 2.24
1.38
3.05
Shiller P/E 115.25
CELG's Shiller P/E is ranked lower than
77% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 45.29 vs. CELG: 115.25 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s Shiller P/E Range Over the Past 10 Years
Min: 105.05  Med: 148.56 Max: 3211
Current: 115.25
105.05
3211
Current Ratio 3.23
CELG's Current Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CELG: 3.23 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.63 Max: 44.53
Current: 3.23
1.35
44.53
Quick Ratio 3.10
CELG's Quick Ratio is ranked lower than
58% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CELG: 3.10 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.53 Max: 44.15
Current: 3.1
1.13
44.15
Days Inventory 287.73
CELG's Days Inventory is ranked lower than
83% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CELG: 287.73 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 66.12  Med: 181.09 Max: 346.89
Current: 287.73
66.12
346.89
Days Sales Outstanding 50.18
CELG's Days Sales Outstanding is ranked higher than
64% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CELG: 50.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.52 Max: 71.27
Current: 50.18
43.42
71.27
Days Payable 164.56
CELG's Days Payable is ranked higher than
80% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CELG: 164.56 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 105.16 Max: 187.47
Current: 164.56
61.81
187.47

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.61
CELG's Price/Tangible Book is ranked lower than
83% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. CELG: 13.61 )
Ranked among companies with meaningful Price/Tangible Book only.
CELG' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.98  Med: 12.02 Max: 482.25
Current: 13.61
3.98
482.25
Price/Projected FCF 2.60
CELG's Price/Projected FCF is ranked higher than
58% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. CELG: 2.60 )
Ranked among companies with meaningful Price/Projected FCF only.
CELG' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.24  Med: 7.52 Max: 122.67
Current: 2.6
2.24
122.67
Price/Median PS Value 0.90
CELG's Price/Median PS Value is ranked higher than
50% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. CELG: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
CELG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.24 Max: 5.75
Current: 0.9
0.52
5.75
Price/Peter Lynch Fair Value 2.51
CELG's Price/Peter Lynch Fair Value is ranked higher than
55% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 1.73 vs. CELG: 2.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CELG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.36  Med: 1.37 Max: 5.1
Current: 2.51
0.36
5.1
Price/Graham Number 5.65
CELG's Price/Graham Number is ranked lower than
80% of the 431 Companies
in the Global Biotechnology industry.

( Industry Median: 2.37 vs. CELG: 5.65 )
Ranked among companies with meaningful Price/Graham Number only.
CELG' s Price/Graham Number Range Over the Past 10 Years
Min: 2.92  Med: 7.51 Max: 30.62
Current: 5.65
2.92
30.62
Earnings Yield (Greenblatt) (%) 2.41
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CELG: 2.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 2.70 Max: 6.7
Current: 2.41
0.6
6.7
Forward Rate of Return (Yacktman) (%) 22.66
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. CELG: 22.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.60 Max: 34.8
Current: 22.66
0.1
34.8

More Statistics

Revenue(Mil) $9256
EPS $ 1.94
Beta1.86
Short Percentage of Float1.33%
52-Week Range $92.98 - 140.72
Shares Outstanding(Mil)785.65

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 11,269 13,459 16,247
EPS($) 5.72 7.17 8.98
EPS without NRI($) 5.72 7.17 8.98

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 
Taking a Look at Barron’s 10 Favorite Stocks for 2016 Dec 07 2015 
Celgene: A Primer on Growth Stock Value Investing - Part 2 Nov 13 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 

More From Other Websites
The Secret’s Out: These Tech Gems Will Go Higher Feb 12 2016
CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Feb 12 2016
CELGENE CORP /DE/ Files SEC form 10-K, Annual Report Feb 11 2016
Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher Feb 11 2016
Amgen, Celgene Buck Short Interest Trend In Biotech Stocks Feb 11 2016
Celgene Corporation Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors Feb 11 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
With $50M round, Peninsula biotech bets on next-generation cancer drug combos Feb 10 2016
Major Biotech Short Interest Continues to Be Mixed Feb 10 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
Rebound For Big Biotech ETF Will Require Some Patience Feb 09 2016
Lightning Round: It's finally in the sweet spot Feb 08 2016
Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place Feb 08 2016
Why GoPro, Microsoft, Twitter and Two Other Stocks Are in Spotlight Today Feb 08 2016
Why Celgene (CELG) Stock Could Increase Today Feb 08 2016
Early movers: HAS, DO, CTSH, APOL, TWTR & more Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK